The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study

Rinkoo Dalan; Li Wei Ang; Wilnard Y T Tan; Siew-Wai Fong; Woo Chiao Tay; Yi-Hao Chan; Laurent Renia; Lisa F P Ng; David Chien Lye; Daniel E K Chew; Barnaby E Young

doi:10.1093/ehjcvp/pvaa098

The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study

Eur Heart J Cardiovasc Pharmacother. 2021 May 23;7(3):e48-e51. doi: 10.1093/ehjcvp/pvaa098.

Authors

Affiliations

¹ Department of Endocrinology, Tan Tock Seng Hospital, Lee Kong Chian School of Medicine, Singapore.
² National Centre for Infectious Diseases, Singapore.
³ Singapore Immunology Network, Agency for Science, Technology and Research, Singapore.
⁴ Department of Biological Sciences, National University of Singapore, Singapore.
⁵ National Centre for Infectious Diseases, Tan Tock Seng Hospital, Lee Kong Chian School of Medicine, Yong Loo Lin School of Medicine, Singapore.

No abstract available

Keywords: Angiotensin receptor blocker (ARB); Angiotensin-converting enzyme inhibitor (ACE-I); Diabetes; Dipeptidyl peptidase 4 inhibitor (DPP4i); Hypertension.

Publication types

Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 / complications*
Cohort Studies
Diabetes Complications / complications*
Diabetes Mellitus / drug therapy*
Humans
Hypertension / complications*
Hypertension / drug therapy*
Retrospective Studies
Severity of Illness Index